title: Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.
abstract: We studied whether a triple dose of gadolinium-DTPA alone or in combination with delayed scanning increases the sensitivity of brain MRI for detecting enhancing lesions in patients with MS. We obtained T1-weighted brain MRI scans in two sessions for 22 patients with clinically definite MS. In the first session, we obtained one scan 5 to 7 minutes after the injection of 0.1 mmol/kg gadolinium-DTPA (standard dose). In the second session, 6 to 24 hours later, we obtained one scan before the two scans 5 to 7 minutes (for all patients) and one hour (for 11 patients) after the injection of 0.3 mmol/kg gadolinium-DTPA (triple dose). We detected 83 enhancing lesions in 14 patients when the standard dose of gadolinium-DTPA was used. The numbers of enhancing lesions increased to 138 (average increase 66%; p = 0.001) and the numbers of patients with such lesions to 18 (increase 28%) when we used the triple dose of gadolinium-DTPA. In addition, the total area per patient occupied by such lesions was greater (p < 0.0001) and lesion signal intensity higher (p = 0.0001) on the triple-dose scans than the standard-dose scans. There was an increase in the number of large enhancing lesions (p = 0.03) in the scans obtained 1 hour after the injection of the triple dose of gadolinium-DTPA. These data indicate that in patients with MS, a triple dose of gadolinium-DTPA can reveal many more enhancing lesions, which also appear larger. This suggests that the pathologic nature of "active" lesions in MS is heterogeneous, which might have impact on planning clinical trials.
authors.affiliation: Department of Neurology, Scientific Institute Ospedale San Raffaele, University of Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Filippi
authors.forename: T
authors.initials: T
authors.lastname: Yousry
authors.forename: A
authors.initials: A
authors.lastname: Campi
authors.forename: C
authors.initials: C
authors.lastname: Kandziora
authors.forename: B
authors.initials: B
authors.lastname: Colombo
authors.forename: R
authors.initials: R
authors.lastname: Voltz
authors.forename: V
authors.initials: V
authors.lastname: Martinelli
authors.forename: S
authors.initials: S
authors.lastname: Spuler
authors.forename: S
authors.initials: S
authors.lastname: Bressi
authors.forename: G
authors.initials: G
authors.lastname: Scotti
authors.forename: G
authors.initials: G
authors.lastname: Comi
mesh_terms: D003287:Contrast Media; D004305:Dose-Response Relationship, Drug; D005682:Gadolinium; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009103:Multiple Sclerosis / Q000473:pathology* / Q000503:physiopathology; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D013116:Spinal Cord / Q000473:pathology*; D013997:Time Factors
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA